Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name

Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs.

The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.